It was found that increased the expression of intracellular ROS could upregulate the sensitivity of NSCLC cells to a certain extent, which could be used as a new marker for diagnosis and treatment.83 In addition, ABT-263 was found to induce apoptosis in human oral cancer-derived cell lines via increasing the expression of C/EBP-homologous protein (CHOP) and its mRNA.84 A selective Bcl-2 inhibitor, ABT-199 (Venetoclax), has received FDA approval for the treatment of chronic lymphocytic leukemia (CLL) and acute myelocytic leukemia (AML). Here, BCL2 is linked to non-small cell lung carcinoma.